ArticleApplied biochemistry and biotechnology2026
m6A Modified VCAN Promotes Glomerular Endothelial Cells Injury and Diabetic Nephropathy by SHH Pathway.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Versican (VCAN) was found to facilitate diabetic nephropathy (DN) progression and be an effective diagnostic indicator of DN. However, the underlying mechanism of VCAN in the modulation of the apoptosis, inflammation and oxidative stress of DN is not revealed. In this study, we found that VCAN was up-regulated in kidney tissues from DN patients and high glucose (HG)-induced human renal glomerular endothelial cells (HRGECs). VCAN knockdown facilitated HG-induced HRGECs viability, reduced HRGECs apoptosis, decreased inflammatory cytokine levels (IL-1β, IL-6 and TNF-α), repressed reactive oxygen species (ROS) and malondialdehyde (MDA) levels and increased superoxide dismutase (SOD) level. Besides, RNA N6-methyladenosine (m6A) expression was increased in HG-induced HRGECs. Methyltransferase-like 14 (METTL14) knockdown decreased VCAN protein level and repressed m6A modification level of VCAN. METTL14 knockdown also reduced VCAN mRNA stability in HRGECs cells by actinomycin D treatment, and suppressed the luciferase activity of VCAN WT in HRGECs. Moreover, METTL14 knockdown increased HG-induced HRGECs viability, decreased the apoptosis, down-regulated inflammatory cytokine levels and ROS level, but VCAN overexpression reversed these results. VCAN knockdown reduced sonic hedgehog (SHH), smoothened (SMO) and Gli1 protein levels, whereas Hedgehog pathway activator purmorphamine (PUR) reversed the inhibition of si-VCAN on these findings. VCAN knockdown reduced glomerular area and collagen deposition, alleviated mesangial matrix expansion, renal tubular injury and glomerular endothelial cells apoptosis in db/db mice. Therefore, VCAN was up-regulated in DN, and VCAN knockdown attenuated the apoptosis, inflammation and oxidative stress in HG-induced HRGECs and db/db mice via SHH signaling.
Indexed as
Identifiers
41706402What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.